|
|
Title:
Methods of inhibiting secretion of follicle-stimulating hormone and
testosterone
United States Patent: 7,754,220
Issued: July 13, 2010
Inventors: Ohtaki; Tetsuya
(Ibaraki, JP), Matsui; Hisanori (Ibaraki, JP), Matsumoto; Hirokazu
(Ibaraki, JP), Kitada; Chieko (Osaka, JP)
Assignee: Takeda
Pharmaceutical Company Limited (Osaka, JP)
Appl. No.: 10/547,974
Filed: March 11, 2004
PCT Filed: March 11, 2004
PCT No.: PCT/JP2004/003226
371(c)(1),(2),(4) Date: May
04, 2006
PCT Pub. No.: WO2004/080479
PCT Pub. Date: September
23, 2004
|
|
|
Outsourcing Guide
|
Abstract
Metastin, compounds that promote the
activity of metastin or its receptors and the like are excellent gonadal
function improving agents, ovulation inducers or promoters, gonadotropic
hormone secretion promoters, gonadotropic hormone secretion inhibitors,
sex hormone secretion promoters, sex hormone secretion inhibitors, etc.,
and can be used as agents for preventing/treating sterility,
hormone-sensitive cancers, endometriosis, etc. Metastin and its receptors
are useful for screening for these pharmaceuticals.
Description of the
Invention
Under the present circumstances, the
present inventors made extensive investigations and have thus found that
human metastin has a gonadotropin release-promoting effect, a gonadal
function improving effect, an ovulation promoting effect, etc. The
inventors have further clarified that ovulation by metastin is a
phenomenon of ovulation mediated by normal differentiation of
estrogen-producing granulosa cells into progesterone-producing luteal
cells, and continuous administration of metastin reduces the release of
gonadotropins and production of testosterone in the testis. As a result of
further studies, the inventors have come to accomplish the present
invention.
More specifically, the present invention relates to the following
features, and so on.
(1) A gonadal function improving agent, which comprises a polypeptide
comprising the same or substantially the same amino acid sequence as the
amino acid sequence represented by SEQ ID NO: 1, or a salt thereof.
(2) The gonadal function improving agent according to (1), which comprises
a polypeptide consisting of the amino acid sequence represented by SEQ ID
NO: 3, or a salt thereof.
(2a) The gonadal function improving agent according to (1), which
comprises a polypeptide consisting of the amino acid sequence represented
by SEQ ID NO: 9, SEQ ID NO: 11, SEQ ID NO: 13 or SEQ ID NO: 15, or a salt
thereof.
(3) The gonadal function improving agent according to (1), wherein the
amino acid sequence which is substantially the same as the amino acid
sequence represented by SEQ ID NO: 1 is the amino acid sequence
represented by SEQ ID NO: 2.
(3a) The gonadal function improving agent according to (1), which
comprises a polypeptide consisting of the amino acid sequence represented
by SEQ ID NO: 5, or a salt thereof.
(3b) The gonadal function improving agent according to (1), which
comprises a polypeptide consisting of the amino acid sequence represented
by SEQ ID NO: 7, or a salt thereof.
(4) A gonadal function improving agent, which comprises a polynucleotide
encoding a polypeptide comprising the same or substantially the same amino
acid sequence as the amino acid sequence represented by SEQ ID NO: 1, or a
salt thereof.
(4a) A gonadal function improving agent, which comprises a polynucleotide
consisting of the base sequence represented by SEQ ID NO: 4, SEQ ID NO: 6,
SEQ ID NO: 8, SEQ ID NO: 10, SEQ ID NO: 12, SEQ ID NO: 14, SEQ ID NO: 16,
SEQ ID NO: 17, SEQ ID NO: 18 or SEQ ID NO: 19.
(5) A gonadal function improving agent, which comprises a compound or its
salt that promotes the activity of a polypeptide comprising the same or
substantially the same amino acid sequence as the amino acid sequence
represented by SEQ ID NO: 1, or a salt thereof.
(5a) The gonadal function improving agent according to (5), wherein the
compound is a compound that promotes the activity of a polypeptide
consisting of the amino acid sequence represented by SEQ ID NO: 3, or a
salt thereof.
(6) A gonadal function improving agent, which comprises a compound or its
salt that promotes the activity of a protein comprising the same or
substantially the same amino acid sequence as the amino acid sequence
represented by SEQ ID NO: 20, its partial peptide, or a salt thereof.
(7) A gonadal function improving agent, which comprises a compound or its
salt that promotes the activation of a polypeptide comprising the same or
substantially the same amino acid sequence as the amino acid sequence
represented by SEQ ID NO: 1, or a salt thereof, into a protein comprising
the same or substantially the same amino acid sequence as the amino acid
sequence represented by SEQ ID NO: 20, its partial peptide, or a salt
thereof.
(8) The gonadal function improving agent according to (1) through (7),
which is an agent for preventing/treating sterility.
(9) The gonadal function improving agent according to (1) through (7),
which is an ovulation inducer or promoter.
(10) The gonadal function improving agent according to (1) through (7),
which is a gonadotropic hormone secretion promoter.
(11) The gonadal function improving agent according to (1) through (7),
which is a gonadotropic hormone secretion inhibitor.
(12) The gonadal function improving agent according to (1) through (7),
which is a sex hormone secretion promoter.
(12a) The gonadal function improving agent according to (12), wherein the
sex hormone is an androgen (testosterone, androstenedione, etc.), an
estrogen (estradiol, estrone, etc.) or progesterone.
(13) The gonadal function improving agent according to (1) through (7),
which is a sex hormone secretion inhibitor.
(13a) The gonadal function improving agent according to (13), wherein the
sex hormone is an androgen (testosterone, androstenedione, etc.), an
estrogen (estradiol, estrone, etc.) or progesterone.
(14) The gonadal function improving agent according to (1) through (7),
which is an agent for preventing/treating a hormone-sensitive cancer.
(15) The gonadal function improving agent according to (1) through (7),
which is an agent for preventing/treating endometriosis.
(16) A diagnostic agent for sterility, which comprises a polynucleotide
encoding a polypeptide comprising the same or substantially the same amino
acid sequence as the amino acid sequence represented by SEQ ID NO: 1, or a
salt thereof, or a polynucleotide encoding a protein comprising the same
or substantially the same amino acid sequence as the amino acid sequence
represented by SEQ ID NO: 20, its partial peptide, or a salt thereof.
(17) A diagnostic agent for sterility, which comprises an antibody to a
polypeptide comprising the same or substantially the same amino acid
sequence as the amino acid sequence represented by SEQ ID NO: 1, or a salt
thereof, or an antibody to a protein comprising the same or substantially
the same amino acid sequence as the amino acid sequence represented by SEQ
ID NO: 20, its partial peptide, or a salt thereof.
(18) A method of screening for a gonadal function improving agent, which
comprises using a polypeptide comprising the same or substantially the
same amino acid sequence as the amino acid sequence represented by SEQ ID
NO: 1, or a salt thereof, and/or a protein comprising the same or
substantially the same amino acid sequence as the amino acid sequence
represented by SEQ ID NO: 20, its partial peptide, or a salt thereof.
(19) The screening method according to (18), wherein the gonadal function
improving agent is a sex hormone secretion inhibitor or a sex hormone
secretion promoter.
(20) The screening method according to (18), wherein the gonadal function
improving agent is a gonadotropic hormone secretion inhibitor or a
gonadotropic hormone secretion promoter.
(21) A kit for screening for a gonadal function improving agent, which
comprises a polypeptide comprising the same or substantially the same
amino acid sequence as the amino acid sequence represented by SEQ ID NO:
1, or a salt thereof, and/or a protein comprising the same or
substantially the same amino acid sequence as the amino acid sequence
represented by SEQ ID NO: 20, its partial peptide, or a salt thereof.
(22) A method of screening for a gonadal function improving agent, which
comprises using a polynucleotide encoding a polypeptide comprising the
same or substantially the same amino acid sequence as the amino acid
sequence represented by SEQ ID NO: 1, or a salt thereof, and/or a
polynucleotide encoding a protein comprising the same or substantially the
same amino acid sequence as the amino acid sequence represented by SEQ ID
NO: 20, its partial peptide, or a salt thereof.
(23) A kit for screening for a gonadal function improving agent, which
comprises a polynucleotide encoding a polypeptide comprising the same or
substantially the same amino acid sequence as the amino acid sequence
represented by SEQ ID NO: 1, or a salt thereof, and/or a polynucleotide
encoding a protein comprising the same or substantially the same amino
acid sequence as the amino acid sequence represented by SEQ ID NO: 20, its
partial peptide, or a salt thereof.
(23a) A gonadal function improving agent, which is obtainable using the
screening method according to (18) or (22), or using the screening kit
according to (21) or (23).
(23b) The gonadal function improving agent according to (23a), which is an
agent for preventing/treating sterility.
(23c) The gonadal function improving agent according to (23a), which is an
ovulation inducer or promoter.
(23d) The gonadal function improving agent according to (23a), which is a
gonadotropic hormone secretion promoter or inhibitor.
(23e) The gonadal function improving agent according to (23a), which is a
sex hormone secretion promoter or inhibitor.
(24) A method of improving gonadal function, which comprises administering
to a mammal an effective dose of (i) a polypeptide comprising the same or
substantially the same amino acid sequence as the amino acid sequence
represented by SEQ ID NO: 1, or a salt thereof, (ii) a polynucleotide
encoding said polypeptide or a salt thereof, (iii) a compound or its salt
that promotes the activity of said polypeptide or a salt thereof, (iv) a
compound or its salt that promotes the activity of a protein comprising
the same or substantially the same amino acid sequence as the amino acid
sequence represented by SEQ ID NO: 20, its partial peptide, or a salt
thereof, or (v) a compound or its salt that promotes the activation of
said polypeptide or a salt thereof into said protein, its partial peptide,
or a salt thereof.
(25) A method of improving gonadal function, which comprises (i) promoting
the activity of a polypeptide comprising the same or substantially the
same amino acid sequence as the amino acid sequence represented by SEQ ID
NO: 1, or a salt thereof, (ii) promoting the activity of a protein
comprising the same or substantially the same amino acid sequence as the
amino acid sequence represented by SEQ ID NO: 20, its partial peptide, or
a salt thereof, or (iii) promoting the activation of said polypeptide or a
salt thereof into said protein, its partial peptide, or a salt thereof.
(26) Use of (i) a polypeptide comprising the same or substantially the
same amino acid sequence as the amino acid sequence represented by SEQ ID
NO: 1, or a salt thereof, (ii) a polynucleotide encoding said polypeptide
or a salt thereof, (iii) a compound or its salt that promotes the activity
of said polypeptide or a salt thereof, (iv) a compound or its salt that
promotes the activity of a protein comprising the same or substantially
the same amino acid sequence as the amino acid sequence represented by SEQ
ID NO: 20, its partial peptide, or a salt thereof, or (v) a compound or
its salt that promotes the activation of said polypeptide or a salt
thereof into said protein, its partial peptide, or a salt thereof, to
manufacture a gonadal function improving agent.
(27) A method of inhibiting gonadotropic hormone secretion and/or a method
of inhibiting sex hormone secretion, which comprises uninterruptedly or
continuously administering to a mammal an effective dose of (i) a
polypeptide comprising the same or substantially the same amino acid
sequence as the amino acid sequence represented by SEQ ID NO: 1, or a salt
thereof, (ii) a polynucleotide encoding said polypeptide or a salt
thereof, (iii) a compound or its salt that promotes the activity of said
polypeptide or a salt thereof, (iv) a compound or its salt that promotes
the activity of a protein comprising the same or substantially the same
amino acid sequence as the amino acid sequence represented by SEQ ID NO:
20, its partial peptide, or a salt thereof, or (v) a compound or its salt
that promotes the activation of said polypeptide or a salt thereof into
said protein, its partial peptide, or a salt thereof.
(27a) A method of inhibiting gonadotropic hormone secretion, which
comprises administering to a mammal an effective dose of (i) a polypeptide
comprising the same or substantially the same amino acid sequence as the
amino acid sequence represented by SEQ ID NO: 1, or a salt thereof, (ii) a
polynucleotide encoding said polypeptide or a salt thereof, (iii) a
compound or its salt that promotes the activity of said polypeptide or a
salt thereof, (iv) a compound or its salt that promotes the activity of a
protein comprising the same or substantially the same amino acid sequence
as the amino acid sequence represented by SEQ ID NO: 20, its partial
peptide, or a salt thereof, or (v) a compound or its salt that promotes
the activation of said polypeptide or a salt thereof into said protein,
its partial peptide, or a salt thereof, which dose is sufficient to
inhibit gonadotropic hormone secretion, which dose is sufficient to
inhibit gonadotropic hormone secretion.
(27b) A method of inhibiting sex hormone secretion, which comprises
administering to a mammal an effective dose of (i) a polypeptide
comprising the same or substantially the same amino acid sequence as the
amino acid sequence represented by SEQ ID NO: 1, or a salt thereof, (ii) a
polynucleotide encoding said polypeptide or a salt thereof, (iii) a
compound or its salt that promotes the activity of said polypeptide or a
salt thereof, (iv) a compound or its salt that promotes the activity of a
protein comprising the same or substantially the same amino acid sequence
as the amino acid sequence represented by SEQ ID NO: 20, its partial
peptide, or a salt thereof, or (v) a compound or its salt that promotes
the activation of said polypeptide or a salt thereof into said protein,
its partial peptide, or a salt thereof, which dose is sufficient to
inhibit sex hormone secretion, which dose is sufficient to inhibit sex
hormone secretion.
(27c) A method of inhibiting gonadotropic hormone secretion, which
comprises administering to a mammal an effective dose of an agonist for a
protein comprising the same or substantially the same amino acid sequence
as the amino acid sequence represented by SEQ ID NO: 20, its partial
peptide, or a salt thereof, which dose is sufficient to inhibit
gonadotropic hormone secretion, which dose is sufficient to inhibit
gonadotropic hormone secretion.
(27d) A method of inhibiting sex hormone secretion, which comprises
administering to a mammal an effective dose of an agonist for a protein
comprising the same or substantially the same amino acid sequence as the
amino acid sequence represented by SEQ ID NO: 20, its partial peptide, or
a salt thereof, which dose is sufficient to inhibit sex hormone secretion,
which dose is sufficient to inhibit sex hormone secretion.
(27e) A method of inhibiting gonadotropic hormone secretion, which
comprises retaining in a mammal at the site or tissue where the
pharmaceutical effects are to be exhibited, at a level more than required,
(i) a polypeptide comprising the same or substantially the same amino acid
sequence as the amino acid sequence represented by SEQ ID NO: 1, or a salt
thereof, (ii) a polynucleotide encoding said polypeptide or a salt
thereof, (iii) a compound or its salt that promotes the activity of said
polypeptide or a salt thereof, (iv) a compound or its salt that promotes
the activity of a protein comprising the same or substantially the same
amino acid sequence as the amino acid sequence represented by SEQ ID NO:
20, its partial peptide, or a salt thereof, or (v) a compound or its salt
that promotes the activation of said polypeptide or a salt thereof into
said protein, its partial peptide, or a salt thereof.
(27f) A method of inhibiting sex hormone secretion, which comprises
retaining in a mammal at the site or tissue where the pharmaceutical
effects are to be exhibited, at a level more than required, (i) a
polypeptide comprising the same or substantially the same amino acid
sequence as the amino acid sequence represented by SEQ ID NO: 1, or a salt
thereof, (ii) a polynucleotide encoding said polypeptide or a salt
thereof, (iii) a compound or its salt that promotes the activity of said
polypeptide or a salt thereof, (iv) a compound or its salt that promotes
the activity of a protein comprising the same or substantially the same
amino acid sequence as the amino acid sequence represented by SEQ ID NO:
20, its partial peptide, or a salt thereof, or (v) a compound or its salt
that promotes the activation of said polypeptide or a salt thereof into
said protein, its partial peptide, or a salt thereof.
(27g) A method of inhibiting gonadotropic hormone secretion, which
comprises retaining in a mammal at the site or tissue where the
pharmaceutical effects are to be exhibited, at a level more than required,
an agonist for a protein comprising the same or substantially the same
amino acid sequence as the amino acid sequence represented by SEQ ID NO:
20, its partial peptide, or a salt thereof.
(27h) A method of inhibiting sex hormone secretion, which comprises
retaining in a mammal at the site or tissue where the pharmaceutical
effects are to be exhibited, at a level more than required, an agonist for
a protein comprising the same or substantially the same amino acid
sequence as the amino acid sequence represented by SEQ ID NO: 20, its
partial peptide, or a salt thereof.
(28) A method of preventing/treating a hormone-sensitive cancer or
endometriosis, which comprises uninterruptedly or continuously
administering to a mammal an effective dose of (i) a polypeptide
comprising the same or substantially the same amino acid sequence as the
amino acid sequence represented by SEQ ID NO: 1, or a salt thereof, (ii) a
polynucleotide encoding said polypeptide or a salt thereof, (iii) a
compound or its salt that promotes the activity of said polypeptide or a
salt thereof, (iv) a compound or its salt that promotes the activity of a
protein comprising the same or substantially the same amino acid sequence
as the amino acid sequence represented by SEQ ID NO: 20, its partial
peptide, or a salt thereof, or (v) a compound or its salt that promotes
the activation of said polypeptide or a salt thereof into said protein,
its partial peptide, or a salt thereof.
(28a) A method of preventing/treating a hormone-sensitive cancer or
endometriosis, which comprises administering to a mammal an effective dose
of (i) a polypeptide comprising the same or substantially the same amino
acid sequence as the amino acid sequence represented by SEQ ID NO: 1, or a
salt thereof, (ii) a polynucleotide encoding said polypeptide or a salt
thereof, (iii) a compound or its salt that promotes the activity of said
polypeptide or a salt thereof, (iv) a compound or its salt that promotes
the activity of a protein comprising the same or substantially the same
amino acid sequence as the amino acid sequence represented by SEQ ID NO:
20, its partial peptide, or a salt thereof, or (v) a compound or its salt
that promotes the activation of said polypeptide or a salt thereof into
said protein, its partial peptide, or a salt thereof, which dose is
sufficient to give a preventive/therapeutic effect on the
hormone-sensitive cancer or endometriosis.
(28b) A method of preventing/treating a hormone-sensitive cancer or
endometriosis, which comprises administering to a mammal an effective dose
of an agonist for a protein comprising the same or substantially the same
amino acid sequence as the amino acid sequence represented by SEQ ID NO:
20, its partial peptide, or a salt thereof, which dose is sufficient to
give a preventive/therapeutic effect on the hormone-sensitive cancer or
endometriosis.
(28c) A method of preventing/treating a hormone-sensitive cancer or
endometriosis, which comprises retaining in a mammal at the site or tissue
where the pharmaceutical effects are to be exhibited, at a level more than
required, (i) a polypeptide comprising the same or substantially the same
amino acid sequence as the amino acid sequence represented by SEQ ID NO:
1, or a salt thereof, (ii) a polynucleotide encoding said polypeptide or a
salt thereof, (iii) a compound or its salt that promotes the activity of
said polypeptide or a salt thereof, (iv) a compound or its salt that
promotes the activity of a protein comprising the same or substantially
the same amino acid sequence as the amino acid sequence represented by SEQ
ID NO: 20, its partial peptide, or a salt thereof, or (v) a compound or
its salt that promotes the activation of said polypeptide or a salt
thereof into said protein, its partial peptide, or a salt thereof.
(28d) A method of preventing/treating a hormone-sensitive cancer or
endometriosis, which comprises retaining in a mammal at the site or tissue
where the pharmaceutical effects are to be exhibited, at a level more than
required, an agonist for a protein comprising the same or substantially
the same amino acid sequence as the amino acid sequence represented by SEQ
ID NO: 20, its partial peptide, or a salt thereof.
(29) A method of inhibiting follicular maturation and/or a method of
suspending a menstrual cycle, which comprises uninterruptedly or
continuously administering to a mammal an effective dose of (i) a
polypeptide comprising the same or substantially the same amino acid
sequence as the amino acid sequence represented by SEQ ID NO: 1, or a salt
thereof, (ii) a polynucleotide encoding said polypeptide or a salt
thereof, (iii) a compound or its salt that promotes the activity of said
polypeptide or a salt thereof, (iv) a compound or its salt that promotes
the activity of a protein comprising the same or substantially the same
amino acid sequence as the amino acid sequence represented by SEQ ID NO:
20, its partial peptide, or a salt thereof, or (v) a compound or its salt
that promotes the activation of said polypeptide or a salt thereof into
said protein, its partial peptide, or a salt thereof.
(29a) A method of inhibiting follicular maturation and/or a method of
suspending a menstrual cycle, which comprises administering to a mammal an
effective dose of (i) a polypeptide comprising the same or substantially
the same amino acid sequence as the amino acid sequence represented by SEQ
ID NO: 1, or a salt thereof, (ii) a polynucleotide encoding said
polypeptide or a salt thereof, (iii) a compound or its salt that promotes
the activity of said polypeptide or a salt thereof, (iv) a compound or its
salt that promotes the activity of a protein comprising the same or
substantially the same amino acid sequence as the amino acid sequence
represented by SEQ ID NO: 20, its partial peptide, or a salt thereof, or
(v) a compound or its salt that promotes the activation of said
polypeptide or a salt thereof into said protein, its partial peptide, or a
salt thereof, which dose is sufficient to inhibit the follicular
maturation and/or suspend the menstrual cycle.
(29b) A method of inhibiting follicular maturation and/or a method of
suspending a menstrual cycle, which comprises administering to a mammal an
effective dose of an agonist for a protein comprising the same or
substantially the same amino acid sequence as the amino acid sequence
represented by SEQ ID NO: 20, its partial peptide, or a salt thereof,
which dose is sufficient to inhibit the follicular maturation and/or
suspend the menstrual cycle.
(29c) A method of inhibiting follicular maturation and/or a method of
suspending a menstrual cycle, which comprises retaining in a mammal at the
site or tissue where the pharmaceutical effects are to be exhibited, at a
level more than required, (i) a polypeptide comprising the same or
substantially the same amino acid sequence as the amino acid sequence
represented by SEQ ID NO: 1, or a salt thereof, (ii) a polynucleotide
encoding said polypeptide or a salt thereof, (iii) a compound or its salt
that promotes the activity of said polypeptide or a salt thereof, (iv) a
compound or its salt that promotes the activity of a protein comprising
the same or substantially the same amino acid sequence as the amino acid
sequence represented by SEQ ID NO: 20, its partial peptide, or a salt
thereof, or (v) a compound or its salt that promotes the activation of
said polypeptide or a salt thereof into said protein, its partial peptide,
or a salt thereof.
(29d) A method of inhibiting follicular maturation and/or a method of
suspending a menstrual cycle, which comprises retaining in a mammal at the
site or tissue where the pharmaceutical effects are to be exhibited, at a
level more than required, an agonist for a protein comprising the same or
substantially the same amino acid sequence as the amino acid sequence
represented by SEQ ID NO: 20, its partial peptide, or a salt thereof.
(30) A method of promoting gonadotropic hormone secretion and/or a method
of promoting sex hormone secretion, which comprises applying bolus
administration to a mammal in an effective dose of (i) a polypeptide
comprising the same or substantially the same amino acid sequence as the
amino acid sequence represented by SEQ ID NO: 1, or a salt thereof, (ii) a
polynucleotide encoding said polypeptide or a salt thereof, (iii) a
compound or its salt that promotes the activity of said polypeptide or a
salt thereof, (iv) a compound or its salt that promotes the activity of a
protein comprising the same or substantially the same amino acid sequence
as the amino acid sequence represented by SEQ ID NO: 20, its partial
peptide, or a salt thereof, or (v) a compound or its salt that promotes
the activation of said polypeptide or a salt thereof into said protein,
its partial peptide, or a salt thereof.
(30a) A method of promoting gonadotropic hormone secretion and/or a method
of promoting sex hormone secretion, which comprises administering to a
mammal an effective dose of (i) a polypeptide comprising the same or
substantially the same amino acid sequence as the amino acid sequence
represented by SEQ ID NO: 1, or a salt thereof, (ii) a polynucleotide
encoding said polypeptide or a salt thereof, (iii) a compound or its salt
that promotes the activity of said polypeptide or a salt thereof, (iv) a
compound or its salt that promotes the activity of a protein comprising
the same or substantially the same amino acid sequence as the amino acid
sequence represented by SEQ ID NO: 20, its partial peptide, or a salt
thereof, or (v) a compound or its salt that promotes the activation of
said polypeptide or a salt thereof into said protein, its partial peptide,
or a salt thereof, which dose is sufficient to promote the gonadotropic
hormone secretion and/or promote the sex hormone secretion.
(30b) A method of promoting gonadotropic hormone secretion and/or a method
of promoting sex hormone secretion, which comprises retaining in a mammal
at the site or tissue where the pharmaceutical effects are to be
exhibited, at a level more than required, (i) a polypeptide comprising the
same or substantially the same amino acid sequence as the amino acid
sequence represented by SEQ ID NO: 1, or a salt thereof, (ii) a
polynucleotide encoding said polypeptide or a salt thereof, (iii) a
compound or its salt that promotes the activity of said polypeptide or a
salt thereof, (iv) a compound or its salt that promotes the activity of a
protein comprising the same or substantially the same amino acid sequence
as the amino acid sequence represented by SEQ ID NO: 20, its partial
peptide, or a salt thereof, or (v) a compound or its salt that promotes
the activation of said polypeptide or a salt thereof into said protein,
its partial peptide, or a salt thereof.
(31) A method of inducing or promoting ovulation, which comprises applying
bolus administration to a mammal in an effective dose of (i) a polypeptide
comprising the same or substantially the same amino acid sequence as the
amino acid sequence represented by SEQ ID NO: 1, or a salt thereof, (ii) a
polynucleotide encoding said polypeptide or a salt thereof, (iii) a
compound or its salt that promotes the activity of said polypeptide or a
salt thereof, (iv) a compound or its salt that promotes the activity of a
protein comprising the same or substantially the same amino acid sequence
as the amino acid sequence represented by SEQ ID NO: 20, its partial
peptide, or a salt thereof, or (v) a compound or its salt that promotes
the activation of said polypeptide or a salt thereof into said protein,
its partial peptide, or a salt thereof.
(31a) A method of inducing or promoting ovulation, which comprises
administering to a mammal an effective dose of (i) a polypeptide
comprising the same or substantially the same amino acid sequence as the
amino acid sequence represented by SEQ ID NO: 1, or a salt thereof, (ii) a
polynucleotide encoding said polypeptide or a salt thereof, (iii) a
compound or its salt that promotes the activity of said polypeptide or a
salt thereof, (iv) a compound or its salt that promotes the activity of a
protein comprising the same or substantially the same amino acid sequence
as the amino acid sequence represented by SEQ ID NO: 20, its partial
peptide, or a salt thereof, or (v) a compound or its salt that promotes
the activation of said polypeptide or a salt thereof into said protein,
its partial peptide, or a salt thereof, which dose is sufficient to induce
or promote ovulation.
(31b) A method of inducing or promoting ovulation, which comprises
retaining in a mammal at the site or tissue where the pharmaceutical
effects are to be exhibited, at a level more than required, (i) a
polypeptide comprising the same or substantially the same amino acid
sequence as the amino acid sequence represented by SEQ ID NO: 1, or a salt
thereof, (ii) a polynucleotide encoding said polypeptide or a salt
thereof, (iii) a compound or its salt that promotes the activity of said
polypeptide or a salt thereof, (iv) a compound or its salt that promotes
the activity of a protein comprising the same or substantially the same
amino acid sequence as the amino acid sequence represented by SEQ ID NO:
20, its partial peptide, or a salt thereof, or (v) a compound or its salt
that promotes the activation of said polypeptide or a salt thereof into
said protein, its partial peptide, or a salt thereof.
(32) A method of inhibiting ovulation, a method of regulating ovarian
function, a method of preventing/treating a hormone-sensitive cancer or a
method of preventing/treating endometriosis, which comprises administering
to a mammal an effective dose of (i) a compound or its salt that inhibits
the activity of a polypeptide comprising the same or substantially the
same amino acid sequence as the amino acid sequence represented by SEQ ID
NO: 1, or a salt thereof, (ii) an antibody to said polypeptide or a salt
thereof, (iii) an antisense nucleotide to a polynucleotide encoding said
polypeptide or a salt thereof, (iv) a compound or its salt that inhibits
the activity of a protein comprising the same or substantially the same
amino acid sequence as the amino acid sequence represented by SEQ ID NO:
20, its partial peptide, or a salt thereof, (v) an antibody to the
polypeptide or a salt thereof, or (vi) an antisense polynucleotide to a
polynucleotide encoding said protein, its partial peptide, or a salt
thereof.
(32a) A method of inhibiting ovulation, a method of regulating ovarian
function, a method of preventing/treating a hormone-sensitive cancer or a
method of preventing/treating endometriosis, which comprises administering
to a mammal an effective dose of an antagonist to a protein comprising the
same or substantially the same amino acid sequence as the amino acid
sequence represented by SEQ ID NO: 20, its partial peptide, or a salt
thereof.
Claim 1 of 2 Claims
1. A method of inhibiting secretion of
follicle-stimulating hormone and testosterone in a male mammal, comprising
continuously administering to said male mammal an effective dose of a
polypeptide comprising the amino acid sequence selected from the group
consisting of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 11, SEQ ID NO: 13,
and SEQ ID NO: 15. ____________________________________________
If you want to learn more
about this patent, please go directly to the U.S.
Patent and Trademark Office Web site to access the full
patent.
|